Rapport Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Rapport Therapeutics, Inc. (RAPP) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 3.62% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-03-10
- Rapport Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 3.62%, a 0.55% decline from fiscal 2023.
- Rapport Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 3.64%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 3.62% 10-K · filed 2026-03-10 |
| 2023-12-31 | 3.64% 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |